MaxCyte

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.

To improve clinical care and illuminate our understanding of biology through innovative cell engineering solutions.

Our vision is to provide the most advanced cell engineering solutions to customers, enabling them to unlock greater scientific discovery and progress.

MaxCyte has received numerous awards, including Ernst &Young Emerging Company of the Year, Deloitte Technology Fast 500, Inc. 5000, and Technology Pioneers. Awards from Frost & Sullivan and Red Herring have recognized MaxCyte for its technology innovation and leadership in the cell engineering space.